Agios Pharmaceuticals. has filed a patent for methods of treating pyruvate kinase deficiency, sickle cell disease, or thalassemia using mitapivat or its salt, alone or in combination with other drugs. The patent outlines various dosing regimens and combinations for effective treatment. GlobalData’s report on Agios Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Agios Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Agios Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Agios Pharmaceuticals's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.

Treating pyruvate kinase deficiency, sickle cell disease, thalassemia with mitapivat

Source: United States Patent and Trademark Office (USPTO). Credit: Agios Pharmaceuticals Inc

A recently filed patent (Publication Number: US20240024434A1) outlines a method for treating hemolytic anemia in a subject by administering varying doses of mitapivat sulfate along with a moderate inducer of cytochrome P450 3A4/5 (CYP3A4/5). The method involves administering doses ranging from 10 mg/day to 200 mg/day of mitapivat sulfate, with specific dosing regimens detailed in the claims.

The patent specifies different dosing levels of mitapivat sulfate for treating hemolytic anemia, ranging from 10 mg/day to 200 mg/day, with corresponding administration frequencies. Additionally, the method involves oral administration of mitapivat sulfate in tablet form, with specific tablet compositions detailed in the claims. The tablet composition includes ingredients such as microcrystalline cellulose, mannitol, croscarmellose sodium, and sodium stearyl fumarate. This patent provides a structured approach to treating hemolytic anemia using mitapivat sulfate in combination with a moderate inducer of CYP3A4/5, offering potential advancements in the field of hematology and personalized medicine.

To know more about GlobalData’s detailed insights on Agios Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies